BRPI0720565A2 - anticorpos e mÉtodos para a sua preparaÇço e seu uso - Google Patents

anticorpos e mÉtodos para a sua preparaÇço e seu uso

Info

Publication number
BRPI0720565A2
BRPI0720565A2 BRPI0720565-1A2A BRPI0720565A BRPI0720565A2 BR PI0720565 A2 BRPI0720565 A2 BR PI0720565A2 BR PI0720565 A BRPI0720565 A BR PI0720565A BR PI0720565 A2 BRPI0720565 A2 BR PI0720565A2
Authority
BR
Brazil
Prior art keywords
antibodies
polypeptides
methods
icfs
recombinant
Prior art date
Application number
BRPI0720565-1A2A
Other languages
English (en)
Inventor
Gerhard Frey
Bruce Kimmel
Abraham Anderson
Original Assignee
Mmr Information Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mmr Information Systems Inc filed Critical Mmr Information Systems Inc
Publication of BRPI0720565A2 publication Critical patent/BRPI0720565A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

ANTICORPOS OU FRAGMENTOS SEUS QUE SE LIGAM A ANTÍGENO, COMPOSIÇçO OU FORMULAÇçO FARMACÊUTICA COMPREENDENDO OS MESMOS E USOS. A invenção propõe anticorpos, incluindo anticorpos humanos quiméricos, anticorpos recombinantes, anticorpos sintéticos e ácidos nucléicos que os codificam, e métodos para preparação e uso destas imunoglobulinas. A presente invenção propõe polipeptídeos e modalidades de ácidos nucléicos destes polipeptídeos e/ou anticorpos recombinantes e sintéticos. A invenção também propõe polipeptídeos que compreendem, ou consistem em regiões de estruturas humanas de consenso, ou "Estruturas Independentemente Obtidas por Consenso (ICFs)", ácidos nucléicos que os codificam e bibliotecas e kits que compreendem estas ICFs e/ou anticorpos da invenção, individualmente e em bibliotecas combinatória em combinações.
BRPI0720565-1A2A 2006-12-20 2007-09-14 anticorpos e mÉtodos para a sua preparaÇço e seu uso BRPI0720565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87106906P 2006-12-20 2006-12-20
PCT/US2007/078568 WO2008079466A1 (en) 2006-12-20 2007-09-14 Antibodies and methods for making and using them

Publications (1)

Publication Number Publication Date
BRPI0720565A2 true BRPI0720565A2 (pt) 2013-09-17

Family

ID=39536929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720565-1A2A BRPI0720565A2 (pt) 2006-12-20 2007-09-14 anticorpos e mÉtodos para a sua preparaÇço e seu uso

Country Status (11)

Country Link
US (3) US8465741B2 (pt)
EP (3) EP2121756A4 (pt)
JP (3) JP2010513539A (pt)
KR (2) KR101546441B1 (pt)
CN (2) CN101675074B (pt)
AU (1) AU2007338607B2 (pt)
BR (1) BRPI0720565A2 (pt)
CA (2) CA2673725C (pt)
HK (2) HK1141543A1 (pt)
MX (1) MX2009006659A (pt)
WO (2) WO2008076487A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
EP3196212B1 (en) 2010-02-24 2020-06-03 ImmunoGen, Inc. Immunoconjugates comprising a folate receptor 1 antibody
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP3153583B1 (en) * 2010-12-31 2021-10-20 BioAtla, Inc. Express humanization of antibodies
EP2659270A4 (en) 2010-12-31 2014-05-21 Bioatla Llc GENERATION OF WHOLE MONOCLONAL ANTIBODIES
CA2825791A1 (en) * 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
EA028805B1 (ru) 2011-04-01 2018-01-31 Иммьюноджен, Инк. Способы повышения эффективности folr1 терапии рака
EP2771694A4 (en) 2011-10-26 2015-08-05 Novartis Tiergesundheit Ag MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
IN2014CN04765A (pt) * 2011-12-19 2015-09-18 Univ Rockefeller
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
HUE055856T2 (hu) 2013-08-30 2021-12-28 Immunogen Inc Antitestek és vizsgálatok a folsavreceptor 1 kimutatására
US10844125B2 (en) 2015-03-04 2020-11-24 The Rockefeller University Anti-inflammatory polypeptides
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
MX2019000172A (es) 2016-07-06 2019-09-26 Celgene Corp Anticuerpos con inmunogenicidad baja y usos de estos.
EP3589658A1 (en) * 2017-08-03 2020-01-08 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2020041896A1 (en) * 2018-08-31 2020-03-05 Immune Biosolutions Inc Antibodies specific for ntsr1 and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
JP2023523584A (ja) * 2020-04-24 2023-06-06 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３抗体及びその使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ATE188708T1 (de) * 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000169393A (ja) * 1998-09-30 2000-06-20 Sankyo Co Ltd 抗Ｆａｓ抗体を含有する医薬
EE05458B1 (et) 2000-05-26 2011-08-15 Bristol-Myers Squibb Company CTL4 lahustuvad mutantsed molekulid ja nende kasutamine
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
LT2380911T (lt) 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
WO2005113003A2 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
SG175659A1 (en) * 2004-05-05 2011-11-28 Genentech Inc Preventing autoimmune disease by using an anti-cd20 antibody
US7740847B2 (en) * 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
JP2008541758A (ja) 2005-06-02 2008-11-27 アストラゼネカ エービー Ｃｄ２０に対する抗体およびその使用
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them

Also Published As

Publication number Publication date
EP2716658A3 (en) 2014-10-08
EP2716657A2 (en) 2014-04-09
EP2121756A1 (en) 2009-11-25
MX2009006659A (es) 2009-10-12
KR101546441B1 (ko) 2015-08-24
JP2010513539A (ja) 2010-04-30
CN101675074A (zh) 2010-03-17
US20100104553A1 (en) 2010-04-29
CA2673725A1 (en) 2008-07-03
KR20130118966A (ko) 2013-10-30
EP2121756A4 (en) 2011-08-31
CN101675074B (zh) 2016-02-24
CA2673725C (en) 2016-01-12
WO2008076487A2 (en) 2008-06-26
US8945550B2 (en) 2015-02-03
EP2716657A3 (en) 2014-10-08
EP2716658A2 (en) 2014-04-09
WO2008076487A3 (en) 2008-12-24
WO2008079466A1 (en) 2008-07-03
US20130287766A1 (en) 2013-10-31
KR101378302B1 (ko) 2014-03-28
US8465741B2 (en) 2013-06-18
AU2007338607A1 (en) 2008-07-03
JP2014028812A (ja) 2014-02-13
AU2007338607B2 (en) 2013-03-14
KR20090094849A (ko) 2009-09-08
CN103709249A (zh) 2014-04-09
US20090285813A1 (en) 2009-11-19
HK1141543A1 (zh) 2010-11-12
JP2015145394A (ja) 2015-08-13
CN103709249B (zh) 2016-02-24
CA2832111A1 (en) 2008-07-03
HK1194395A1 (zh) 2014-10-17

Similar Documents

Publication Publication Date Title
BRPI0720565A2 (pt) anticorpos e mÉtodos para a sua preparaÇço e seu uso
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
ECSP088591A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
CL2014001334A1 (es) Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
BRPI0515858A (pt) anticorpos anti-il-12, epìtopos, composições, métodos e usos
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BRPI0806185A2 (pt) anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
BR112012009289A2 (pt) isolamento e purificação de anticorpos anti-il-13 com uso de cromatografia de afinidade com proteína a.
BRPI0712953B8 (pt) anticorpos anti-nkg2a, seu uso, e composição farmacêutica
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
NO20055209D0 (no) Peptabody for cancerbehandling
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
EP1433792A3 (en) Human receptor proteins, related reagents and methods
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
CA2760392C (en) Influenza viral peptides and fusion protein for immunization, methods and uses thereof

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MMRGLOBAL, INC (US)

B25G Requested change of headquarter approved

Owner name: MMRGLOBAL, INC (US)

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]